ArticleAntimicrobial agents and chemotherapy2005
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 138 citations in OpenAlex.
- Outcomes byAntimicrobial agents and chemotherapy · 2024Trial
- Risk factors and outcome for bloodstream infections due to fluconazole-resistant Candida parapsilosis: a 22-year single-center retrospective study.Antimicrobial resistance and infection control · 2025Article
- Clinical and molecular features of candidemia: a three-year retrospective study in Northern Guizhou, China.Frontiers in cellular and infection microbiology · 2025Article
- Molecular Investigation of the Fatal BloodstreamInternational journal of molecular sciences · 2023Article
- Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata.Current biology : CB · 2021Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- "It Takes a Village": Mechanisms Underlying Antimicrobial Recalcitrance of Polymicrobial Biofilms.Journal of bacteriology · 2019Review
- Echinocandin Resistance in Candida Species: a Review of Recent Developments.Current infectious disease reports · 2016Review
- In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.Jundishapur journal of microbiology · 2016Article
- Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children.Mediterranean journal of hematology and infectious diseases · 2016Article
- Clinical perspectives on echinocandin resistance among Candida species.Current opinion in infectious diseases · 2015Review
- Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.Antimicrobial agents and chemotherapy · 2015Article
- Mechanisms of Antifungal Drug Resistance.Cold Spring Harbor perspectives in medicine · 2014Review
- Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.Antimicrobial agents and chemotherapy · 2013Article
- Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.Antimicrobial agents and chemotherapy · 2013Article
- The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Antimicrobial agents and chemotherapy · 2012Article
- The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.Virulence · 2012Review
- Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The caspofungin clinical trial database offers an opportunity to assess susceptibility results for Candida pathogens obtained from patients with candidiasis and allows for correlations between efficacy outcomes and MICs. Candida isolates have been identified from patients enrolled in four studies of esophageal candidiasis and two studies of invasive candidiasis. The MICs of caspofungin for all baseline isolates were measured at a central laboratory using NCCLS criteria (document M-27A); MICs for caspofungin were defined as the lowest concentration inhibiting prominent growth at 24 h. MICs were then compared to clinical and microbiological outcomes across the two diseases. Susceptibility testing for caspofungin was performed on 515 unique baseline isolates of Candida spp. obtained from patients with esophageal candidiasis. MICs for caspofungin ranged from 0.008 to 4 microg/ml; the MIC50 and MIC90 were 0.5 and 1.0 microg/ml, respectively. Susceptibility testing was also performed on 231 unique baseline isolates of Candida spp. from patients with invasive candidiasis. The majority (approximately 96%) of MICs were between 0.125 and 2 microg/ml, with MIC50 and MIC90 for caspofungin being 0.5 and 2.0 microg/ml, respectively. Overall, caspofungin demonstrated potent in vitro activity against clinical isolates of Candida species. A relationship between MIC for caspofungin and treatment outcome was not seen for patients with either esophageal candidiasis or invasive candidiasis. Patients with isolates for which the MICs were highest (>2 microg/ml) had better outcomes than patients with isolates for which the MICs were lower (<1 microg/ml). Additionally, no correlation between MIC and outcome was identified for specific Candida species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.